logo
Controversial rapper slammed for calling LGBTQ+ identities ‘trauma response'

Controversial rapper slammed for calling LGBTQ+ identities ‘trauma response'

Yahooa day ago
A rapper who has became more known for her controversial opinions than her music is under fire once again.
Azealia Banks has sparked backlash for a recent social media post in which she called LGBTQ+ identities 'a trauma response.'
'Well being gay and transgender is not actually a natural thing. At all, it's a trauma response,' Banks, 34, wrote in an X post from Sunday, July 27.
'Science lied to you all and told you, you were normal but being homosexual and on the more extreme end — transgender in any regard is in fact — a trauma response," the rapper wrote. 'No one is born gay, and no one is born in the wrong body. You guys have mental disorders that science is doing you guys a major disservice by not medicating. Bet you didn't know that.'
Social media users were quick to ridicule Banks, calling her words hateful, transphobic and scientifically inaccurate.
'Attraction to the same sex and living outside assigned gender roles aren't modern concepts. They've existed for as long as humans have recorded history, across cultures, continents, and centuries,' one X user commented.
'Being gay is 'unnatural' in the same way that a healthy woman of birthing age can be barren, or a hermaphrodite has genitals unaligned with either sex,' another comment read. 'Out of the ordinary, but definitely still a part of the human condition and nature at large. The trauma thing does not hold up.'
Major health organizations have affirmed that sexual orientation is natural and not a conscious choice that someone makes. Planned Parenthood's website states that 'research shows that sexual orientation is likely caused partly by biological factors that start before birth.'
Meanwhile the American Psychiatric Association and the American Psychological Association have found evidence 'that homosexuality is a normal variant of human sexual orientation as opposed to a mental disorder,' according to a study published by the National Institute of Health — therefore refuting Banks' claim.
'Well someone never bothered to advance their own education,' another X user wrote on the rapper's post.
'It's more ignorant than anything and admittedly embarrassing that you'd want to simplify our entire species down to the smallest boxes that even the entire animal kingdom doesn't follow,' they continued. 'I am embarrassed for and of you.'
Banks, best known for her 2011 hit song '212,' has a history of sharing controversial thoughts on social media and has long been accused of homophobia and transphobia.
In 2015, the rapper was caught calling a flight attendant a '(expletive) faggot' and, in 2016, was banned from X for making racist and homophobic comments about One Direction singer Zayn Malik. A more recent incident happened in 2020 when Banks posted a meme accusing gay people of 'appropriating horse culture,' MetroWeekly reported.
Banks has also made transphobic remarks, most notably in 2021 when she she said that trans women are 'just gay boys on hormones using male aggression to force their ways into women's spaces,' PinkNews reported.
However, in February 2025, Banks started to show support for the transgender community when she criticized author J. K. Rowling's views on trans women.
'All of the insane anti-trans paranoid people like @jk_rowling feel their femininity is threatened for whatever reason and try to mask that insecurity with 'science' like anyone is stupid and doesn't already know these things,' Banks wrote in an X post.
In a follow-up post, Banks shared her experiences of watching her brother, who she said identifies as trans, struggle with their sexual identity.
'I have witnessed first hand the type of misery, pain, ostracism, suicide attempts, unnecessary and unwarranted abuse my mother doled out to my brother, the discomfort with his body,' Banks wrote. 'It's not a mental illness it's a spiritual thing.'
More music content
Original lead singer of iconic metal band dies at 69
Linkin Park to play two shows in Boston, here's how to buy last-minute tickets
Popular band's frontman sued over 2019 post urging hurricane relief donations
Rock star eats at Northeast diner — twice: 'It's a great day'
All the fall 2025 music acts and performances coming to The Big E
Read the original article on MassLive.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Yahoo

timean hour ago

  • Yahoo

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Deion Sanders says he never questioned God during his battle with bladder cancer
Deion Sanders says he never questioned God during his battle with bladder cancer

Fox News

timean hour ago

  • Fox News

Deion Sanders says he never questioned God during his battle with bladder cancer

Deion Sanders revealed Monday he had his bladder removed after he was diagnosed with cancer, but he said he never questioned God, no matter how difficult things were. Sanders, 57, said God has blessed him too much to ask, 'Why me?' "I have never questioned God. You know my faith, man," Sanders said during an interview with Michael Irvin. "I never questioned and ask God. 'Why me?' I can't. Why me am I living like this? Why me am I the coach of the Colorado Buffaloes? Why me am I on this wonderful university? Why me do I have these wonderful kids with my last name? Like, why me that God has blessed me so much. Like, I would have to ask God, 'Why me all that, too?' "So, I never asked God, 'Why me?'" Sanders said he only asked the Lord to show him the way. "I only said, 'Lord, show me. Show me what you trying to do so I can help you expedite the process. Just show me. We got this, Lord. I know I ain't going nowhere,'" Sanders said. "I know for the enemy to try me, you had to say, 'Have you considered my servant crime?' You had to say that for him to even get to me. So I know that, I'm yours. I know what you going to do with me. I know what you going to continue to do with me." The bladder removal has forced Sanders to undergo a complete lifestyle change, which he said he reached out to someone for advice on how to deal with the changes. Sanders urged people to get checked, because he only discovered the cancer in the bladder after an ACT scan of his vascular pattern to determine if his blood clots were away. The Colorado head coach said it was "unbelievable" to be back talking to his players again. Colorado went 9-4 last season and will look to improve on that record this season after losing Heisman Trophy winner Travis Hunter and starting quarterback Shedeur Sanders to the NFL.

Option Care Health, Inc. (OPCH): A Bull Case Theory
Option Care Health, Inc. (OPCH): A Bull Case Theory

Yahoo

time2 hours ago

  • Yahoo

Option Care Health, Inc. (OPCH): A Bull Case Theory

We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store